Mirikizumab (Omvoh) is an anti‐IL‐23 monoclonal antibody for the treatment of moderate to severe ulcerative colitis. This article outlines its administration, clinical trial efficacy, adverse effects and place in therapy.
No takes yet. Share an insight, caveat, or question.
Steve Chaplin (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: